<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04926844</url>
  </required_header>
  <id_info>
    <org_study_id>Soh-Med-21-06-07</org_study_id>
    <nct_id>NCT04926844</nct_id>
  </id_info>
  <brief_title>Effectiveness of Combined Levetiracetam and Midazolam in Generalized Convulsive Status Epilepticus in Children</brief_title>
  <official_title>Effectiveness of Combined Levetiracetam and Midazolam in Treatment of Generalized Convulsive Status Epilepticus in Children</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sohag University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sohag University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Generalized status epilepticus is a common pediatric neurological emergency with significant&#xD;
      mortality and morbidity. Benzodiazepines remain the first anticonvulsive line but&#xD;
      benzo-diazepines don't control seizures in about 30% of cases. GCSE may be more rapidly&#xD;
      stopped and controlled through combining another drug with benzodiazepines such as&#xD;
      Levetiracetam, acting by different pathways. This study aims to evaluate the effectiveness of&#xD;
      combined levetiracetam and midazolam in treatment of generalized convulsive status&#xD;
      epilepticus in children.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Generalized convulsive status epilepticus (GCSE) is a common pediatric neurological emergency&#xD;
      with an annual incidence of up to 73 episodes per 100,000 children and is associated with&#xD;
      mortality in 2.7% of cases and overall morbidity in 10% - 20% of cases, including hemodynamic&#xD;
      instability and long-term neurological impairments.&#xD;
&#xD;
      The management of GCSE in children starts with emergency measures (stabilization phase) with&#xD;
      monitoring and laboratory testing in the first 5 minutes. Benzodiazepines are used as&#xD;
      first-line anticonvulsants for GCSE that persists for more than 5 minutes. However, studies&#xD;
      have shown that benzo-diazepines don't control GCSE in about 30% of patients. GCSE may be&#xD;
      more rapidly stopped and controlled through combining another drug with benzodiazepines,&#xD;
      acting by different pathways.&#xD;
&#xD;
      Levetiracetam is a recent broad-spectrum antiepileptic drug with a relatively high safety&#xD;
      profile. The effectiveness of intravenous levetiracetam has been demonstrated as a&#xD;
      second-line anticonvulsant in GCSE. In this study, we aim to evaluate the effectiveness and&#xD;
      safety of levetiracetam plus midazolam versus midazolam alone as first-line therapy of GCSE&#xD;
      in children.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 20, 2021</start_date>
  <completion_date type="Anticipated">June 2022</completion_date>
  <primary_completion_date type="Anticipated">May 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Two groups of children with continuing seizures after stabilization phase (5 minutes):&#xD;
Study group; will receive intravenous levetiracetam 60 mg/kg (max 4500 mg) over 5 minutes (diluted with isotonic saline to a concentration of 50 mg/ml).&#xD;
Control group will receive intravenous isotonic saline (as a placebo) in the same way. At the same time, both groups will receive intravenous midazolam 0.2 mg/kg (maximum 10 mg) over 2 minutes.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Each enrolled child will be assigned a unique identification number. Pharmacy will fill the active and placebo preparations in similar containers with sealed code for identification. Participants' families, treating clinicians, and investigators will be unaware of group assignment and drug/placebo therapy.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Cessation of seizures</measure>
    <time_frame>20 minutes</time_frame>
    <description>Cessation of clinical seizures at 20 minutes timepoint (end of first therapy phase)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Need for repeating midazolam</measure>
    <time_frame>20 minutes</time_frame>
    <description>Need for repeating midazolam during the first therapy phase (5 - 20 min)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cessation of seizures</measure>
    <time_frame>40 minutes</time_frame>
    <description>Cessation of clinical seizures at 40 minutes timepoint (end of second therapy phase).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Seizure control</measure>
    <time_frame>24 hours</time_frame>
    <description>24-hours seizure control (no visually observed recurrence of seizures after the end of second phase therapy with improved sensorium)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hypotension</measure>
    <time_frame>24 hours</time_frame>
    <description>Occurrence of hypotension</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Need for mechanical ventilation</measure>
    <time_frame>24 hours</time_frame>
    <description>Need for mechanical ventilation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Skin rash</measure>
    <time_frame>24 hours</time_frame>
    <description>Occurrence of skin rash</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Agitation/aggression</measure>
    <time_frame>24 hours</time_frame>
    <description>Occurrence of agitation/aggression</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality</measure>
    <time_frame>24 hours</time_frame>
    <description>Occurrence of death</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">144</enrollment>
  <condition>Status Epilepticus</condition>
  <condition>Generalized Convulsive Status Epilepticus</condition>
  <condition>Status Epilepticus, Generalized</condition>
  <condition>Status Epilepticus, Generalized Convulsive</condition>
  <arm_group>
    <arm_group_label>Study group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Children receiving levetiracetam + midazolam</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Children receiving placebo + midazolam</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Levetiracetam</intervention_name>
    <description>Intravenous levetiracetam 60 mg/kg (max 4500 mg) over 5 minutes (diluted with isotonic saline to a concentration of 50 mg/ml).</description>
    <arm_group_label>Study group</arm_group_label>
    <other_name>Keppra</other_name>
    <other_name>Tiratam</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Midazolam</intervention_name>
    <description>Intravenous midazolam 0.2 mg/kg (maximum 10 mg) over 2 minutes</description>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_label>Study group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Intravenous isotonic saline (1.2 ml/kg) over 5 minutes</description>
    <arm_group_label>Control group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Generalized convulsive status epilepticus, which is clinically defined at the time of&#xD;
             presentation as continuous, generalized, tonic-clonic seizure activity or ≥ 2&#xD;
             generalized tonic-clonic seizures without recovery of consciousness for more than 5&#xD;
             minutes.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Failure to obtain informed consent.&#xD;
&#xD;
          -  Prior therapy with any anticonvulsant for the presenting episode of generalized&#xD;
             convulsive status epilepticus.&#xD;
&#xD;
          -  Epileptic patients on levetiracetam therapy.&#xD;
&#xD;
          -  Known allergy or contraindications to any of the study drugs.&#xD;
&#xD;
          -  End-stage kidney disease.&#xD;
&#xD;
          -  Severe liver disease.&#xD;
&#xD;
          -  Cardiac diseases.&#xD;
&#xD;
          -  Hypoglycemia or hyperglycemia.&#xD;
&#xD;
          -  Inborn errors of metabolism.&#xD;
&#xD;
          -  Known mood/behavioral disorder.&#xD;
&#xD;
          -  Failure to obtain intravenous access in the first 5 minutes.&#xD;
&#xD;
          -  Cessation of seizures during the stabilization phase (0 - 5 minutes).&#xD;
&#xD;
          -  Traumatic brain injury&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Month</minimum_age>
    <maximum_age>16 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Abdelrahim A Sadek, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Sohag University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ahmed Abdelhamid Elshater, MBBCH</last_name>
    <phone>00201069093230</phone>
    <email>ahmed.abdelhameed@med.sohag.edu.eg</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Elsayed Abdelkreem, MD, PhD</last_name>
    <phone>00201114232126</phone>
    <email>d.elsayedmohammed@med.sohag.edu.eg</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Department of Pediatrics - Sohag University Hospital</name>
      <address>
        <city>Sohag</city>
        <zip>82524</zip>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mostafa Abo-Sidera, MD, PhD</last_name>
      <phone>00201002028668</phone>
      <email>aabosdera@yahoo.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <reference>
    <citation>Glauser T, Shinnar S, Gloss D, Alldredge B, Arya R, Bainbridge J, Bare M, Bleck T, Dodson WE, Garrity L, Jagoda A, Lowenstein D, Pellock J, Riviello J, Sloan E, Treiman DM. Evidence-Based Guideline: Treatment of Convulsive Status Epilepticus in Children and Adults: Report of the Guideline Committee of the American Epilepsy Society. Epilepsy Curr. 2016 Jan-Feb;16(1):48-61. doi: 10.5698/1535-7597-16.1.48.</citation>
    <PMID>26900382</PMID>
  </reference>
  <reference>
    <citation>McKenzie KC, Hahn CD, Friedman JN. Emergency management of the paediatric patient with convulsive status epilepticus. Paediatr Child Health. 2021 Jan 21;26(1):50-66. doi: 10.1093/pch/pxaa127. eCollection 2021 Feb. Review. English, French.</citation>
    <PMID>33552322</PMID>
  </reference>
  <reference>
    <citation>Singh A, Stredny CM, Loddenkemper T. Pharmacotherapy for Pediatric Convulsive Status Epilepticus. CNS Drugs. 2020 Jan;34(1):47-63. doi: 10.1007/s40263-019-00690-8. Review.</citation>
    <PMID>31879852</PMID>
  </reference>
  <reference>
    <citation>Hamano SI, Sugai K, Miki M, Tabata T, Fukuyama T, Osawa M. Efficacy, safety, and pharmacokinetics of intravenous midazolam in Japanese children with status epilepticus. J Neurol Sci. 2019 Jan 15;396:150-158. doi: 10.1016/j.jns.2018.09.035. Epub 2018 Oct 4.</citation>
    <PMID>30472551</PMID>
  </reference>
  <reference>
    <citation>Navarro V, Dagron C, Elie C, Lamhaut L, Demeret S, Urien S, An K, Bolgert F, Tréluyer JM, Baulac M, Carli P; SAMUKeppra investigators. Prehospital treatment with levetiracetam plus clonazepam or placebo plus clonazepam in status epilepticus (SAMUKeppra): a randomised, double-blind, phase 3 trial. Lancet Neurol. 2016 Jan;15(1):47-55. doi: 10.1016/S1474-4422(15)00296-3. Epub 2015 Nov 28.</citation>
    <PMID>26627366</PMID>
  </reference>
  <reference>
    <citation>Alvarez V, Rossetti AO. Monotherapy or Polytherapy for First-Line Treatment of SE? J Clin Neurophysiol. 2016 Feb;33(1):14-7. doi: 10.1097/WNP.0000000000000217. Review.</citation>
    <PMID>26840871</PMID>
  </reference>
  <reference>
    <citation>Lynch BA, Lambeng N, Nocka K, Kensel-Hammes P, Bajjalieh SM, Matagne A, Fuks B. The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam. Proc Natl Acad Sci U S A. 2004 Jun 29;101(26):9861-6. Epub 2004 Jun 21.</citation>
    <PMID>15210974</PMID>
  </reference>
  <reference>
    <citation>Klitgaard H, Pitkänen A. Antiepileptogenesis, neuroprotection, and disease modification in the treatment of epilepsy: focus on levetiracetam. Epileptic Disord. 2003 May;5 Suppl 1:S9-16. Review.</citation>
    <PMID>12915336</PMID>
  </reference>
  <reference>
    <citation>Misra UK, Kalita J, Maurya PK. Levetiracetam versus lorazepam in status epilepticus: a randomized, open labeled pilot study. J Neurol. 2012 Apr;259(4):645-8. doi: 10.1007/s00415-011-6227-2. Epub 2011 Sep 6.</citation>
    <PMID>21898137</PMID>
  </reference>
  <reference>
    <citation>Sharpe C, Reiner GE, Davis SL, Nespeca M, Gold JJ, Rasmussen M, Kuperman R, Harbert MJ, Michelson D, Joe P, Wang S, Rismanchi N, Le NM, Mower A, Kim J, Battin MR, Lane B, Honold J, Knodel E, Arnell K, Bridge R, Lee L, Ernstrom K, Raman R, Haas RH; NEOLEV2 INVESTIGATORS. Levetiracetam Versus Phenobarbital for Neonatal Seizures: A Randomized Controlled Trial. Pediatrics. 2020 Jun;145(6). pii: e20193182. doi: 10.1542/peds.2019-3182. Epub 2020 May 8. Erratum in: Pediatrics. 2021 Jan;147(1):.</citation>
    <PMID>32385134</PMID>
  </reference>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>June 14, 2021</study_first_submitted>
  <study_first_submitted_qc>June 14, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 15, 2021</study_first_posted>
  <last_update_submitted>July 2, 2021</last_update_submitted>
  <last_update_submitted_qc>July 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sohag University</investigator_affiliation>
    <investigator_full_name>Ahmed Abdelhamid Elshater</investigator_full_name>
    <investigator_title>Pediatric Resident</investigator_title>
  </responsible_party>
  <keyword>Status epilepticus</keyword>
  <keyword>Convulsions</keyword>
  <keyword>Children</keyword>
  <keyword>Seizures</keyword>
  <keyword>Benzodiazepines</keyword>
  <keyword>Midazolam</keyword>
  <keyword>Levetiracetam</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Status Epilepticus</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Midazolam</mesh_term>
    <mesh_term>Levetiracetam</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Unidentified individual patients' data will be available on resonable request after publication</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_time_frame>After publication for 3 years</ipd_time_frame>
    <ipd_access_criteria>Contact the principal investigator</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

